In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA ...
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents the final overall survival data from the phase 3 FLAURA2 study of osimertinib plus chemotherapy in epidermal growth ...
Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in ...
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center. In this episode ...
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates. In an interview with CancerNetwork®, Ayal Aizer, MD, MHS, ...
The 10-year results from the phase 3 CHN HYPOPMRT trial (NCT00793962) showed that hypofractionated postmastectomy radiotherapy (PMRT) delivered over 3 weeks maintained durable locoregional control ...
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510 (k) supported by the HYDROSPACE trial.
Treatment options for patients with relapsed/refractory follicular lymphoma have expanded rapidly. CD19-directed CAR T-cell therapies are approved in the third-line setting and beyond, and CD20 x CD3 ...
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG ...
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 ...
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable ...
Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results